Program Announced at Rutgers Men's Basketball Game as Part of LG's Life's Good Night PISCATAWAY, N.J. , Dec. 16, 2024 /PRNewswire/ -- LG Electronics USA , a proud partner of Rutgers Athletics, announced the creation of two positions in its annual LG Summer Internship Program exclusively for Rutgers student-athletes. The announcement was made at a recent Rutgers men's basketball game, which also featured a series of Life's Good giveaways for fans, including LG TVs and LG XBOOM Audio products. As part of the company's commitment to fostering young talent, interns will have the chance to work alongside experienced professionals, gaining exposure to various areas of LG's organizations and making important contributions to real-world projects as part of the internship program. "LG is a very meaningful and impactful place to work," said Audrey Cha , a junior at Rutgers and former LG brand marketing summer intern who was on hand to help make the announcement. "I'm really passionate about the field of marketing, and my internship allowed me to experience a lot of real-world work in my field. I was also able to make a lot of connections that I've maintained even after my internship ended," she added. LG also added multiple Life's Good moments throughout the game for the fans. As part of the company's sponsorship, LG brought "Life's Good" to center court at Jersey Mike's Arena with a friendly head-to-head competition and product giveaways. Following the game, fans enjoyed a meet-and-greet with Rutgers guard and team captain, Jeremiah Williams . "LG recognizes the importance of investing in the next generation of leaders, and our internship program provides a unique opportunity for students to gain enriching experiences in a variety of fields in a dynamic corporate environment," said Louis Giagrande , LG USA head of marketing. "We are proud to partner with Rutgers Athletics to support their student-athletes both on and off the court." "LG's summer internship program continues to create exceptional opportunities for our student-athletes," said Carey Loch , Senior Associate Athletic Director for Student-Athlete Development and Success at Rutgers University . "The presence of LG at this game had a powerful impact, energizing fans, strengthening the LG-Rutgers partnership and showcasing LG's investment in our students' futures." In addition to highlighting the internship program, the halftime competition featured a head-to-head challenge where fans tested their basketball shooting skills for a chance to win LG prizes. During the post-game meet and greet with Williams, fans also had the opportunity to take pictures, get his autograph and win LG products including XBOOM XL7 and XBOOM XG2T portable audio speakers. To learn more about LG's commitment to student-athletes, visit https://www.lg.com/us/ncaa . About LG Electronics USA LG Electronics USA , Inc., based in Englewood Cliffs, N.J. , is the North American subsidiary of LG Electronics, Inc., a $68 billion global innovator in technology and manufacturing. In the United States , LG sells a wide range of innovative home appliances, home entertainment products, commercial displays, air conditioning systems and vehicle components. LG is an 11-time ENERGY STAR® Partner of the Year. The company's commitment to environmental sustainability and its "Life's Good" marketing theme encompass how LG is dedicated to people's happiness by exceeding expectations today and tomorrow. www.LG.com . Media Contacts: LG Electronics USA Chris De Maria christopher.demaria@lge.com 908-548-4515 Kristi Hubert Kristi.Hubert@LG-One.com 630-995-5444 View original content to download multimedia: https://www.prnewswire.com/news-releases/lg-usa-announces-creation-of-2025-summer-internships-exclusively-for-rutgers-student-athletes-302332916.html SOURCE LG Electronics USA
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBodyTM, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and efficacy amid growing global demand through the joint research initiative building on the momentum for its radiopharmaceutical therapy business SEOUL, South Korea, Dec. 16, 2024 /PRNewswire/ -- SK Biopharmaceuticals, a biotech company focusing on the research, development and commercialization of treatments for disorders of the central nervous system and oncology worldwide, announced a research collaboration agreement with ProEn Therapeutics, a biotech company dedicated to advancing oncology treatments, to further extend its oncology research capability and expand its pipeline of radiopharmaceutical therapies (RPT). Under this agreement, both sides seek to advance up to two preclinical candidates for the development of novel radiopharmaceutical drugs by 2027 – the year when SK Biopharmaceuticals aims to become a global leading RPT player, via strengthened internal and external resources. This joint research builds on a series of SK Biopharmaceuticals' global strategic partnerships, including the in-licensing of a radiopharmaceutical compound, and a supply agreement to secure actinium-225, an alpha-particle emitting radioisotope, since the company unveiled its "RPT Roadmap" to gain a competitive edge in the rapidly growing field of nuclear medicine. SK Biopharmaceuticals will leverage ProEn Therapeutics' ArtBodyTM platform, a dual-target binding technology that incorporates small proteins[1] to identify and target specific tumor antigens – enhancing tumor selectivity – for the development of potential cancer treatments, while minimizing damage to healthy tissues. ArtBodyTM, which has intrinsic advantages of high stability and structural robustness, can be mass-produced using bacteria, making it ideal for industrial applications. Il-Han Lee, Chief Executive Officer of ProEn Therapeutics, said, "We are pleased to enter this joint research, and positive that the ArtBodyTM platform will generate synergy with and complement SK Biopharmaceuticals' radiopharmaceutical therapy business. ProEn Therapeutics will push to produce the best possible outcome that can meet not only the two companies' expectations, but also patients' needs." Donghoon Lee, Chief Executive Officer of SK Biopharmaceuticals, said, "This collaboration with ProEn Therapeutics is significant as the platform technology will help overcome the limitations of existing therapies. We will aim to develop more effective, safer treatments, while leading global RPT research and development efforts." [1] Small proteins, in contrast to antibodies, offer superior tumor penetration, faster clearance, and greater cost efficiency. These advantages help address key challenges in antibody-based drug development – high manufacturing costs and potential toxicity issues – driving an increasing focus on small proteins from pharma and biotech companies worldwide. About SK Biopharmaceuticals SK Biopharmaceuticals focuses on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology. In 2017, SK Biopharmaceuticals established a research center to begin its expansion into oncology through research and development efforts. SK Biopharmaceuticals is the first and only Korean company to independently develop and commercialize an antiseizure medication, cenobamate (brand name: XCOPRI®), in the U.S. Cenobamate, which was commercially launched in the U.S. in 2020 by SK Biopharmaceuticals and its U.S. subsidiary SK Life Science, has successfully entered five major regions: North America, Europe, Asia, Central and South America, and the Middle East and North Africa. The company has a pipeline of eight compounds in development in both CNS disorders and oncology. For more information, visit SK Biopharmaceuticals' website at , and SK Life Science's website at . About ProEn Therapeutics ProEn Therapeutics is a biotechnology company dedicated to advancing oncology treatments through cutting-edge protein engineering. The company's innovative drug development platform, ArtBodyTM, focuses on bi-specific antibody-drug conjugates tailored for solid cancers. ProEn Therapeutics is also exploring next-generation therapies such as immune cell engagers and chimeric antigen receptor platforms, while extending its research in radiopharmaceuticals. The company is advancing its proprietary pipeline, while actively collaborating with partners specializing in various therapeutic modalities. For more information, visit ProEn Therapeutics' website at . SOURCE SK Biopharmaceuticals MENAFN16122024003732001241ID1108999948 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Biratnagar, Nov 24: Koshi Province Government Chief Minister Hikmat Kumar Karki has stressed on slashing the unnecessary expenditure and increasing the capital spending. Addressing a discussions programme organized by the High Level Economic Reforms Recommendation Commission at the Office of the Chief Minister and Council of Ministers here today, Chief Minister Karki insisted on 'stopping the flood of infrastructure'. He said works should be carried out prioritizing on development of national capital, and attention should be given to promoting tourism, information technology, agriculture, and construction sectors. "Policy capable of increasing domestic products and encouraging export-oriented enterprises should be brought and the federal government should support the province and local levels on the basis of their capacity," Chief Minister Karki said. Stating that economic reforms could not be achieved also due to the lack of responsibility and accountability, he called for carrying out works on the model of accountability and collaboration on topics as administrative reforms and revenue mobilization for achieving the desired results. Koshi provincial government's Minister for Economic Affairs and Planning, Ram Bahadur Magar underscored on promotion of small capital along with large capital. He added that export-oriented industries should be encouraged. The provincial government ministers and ministry secretaries also attended the discussions. On the occasion, they gave suggestions as simplifying the Acts and Regulations, making the role of the regulatory bodies effective, carrying out works by delegating rights as per the spirit of federalism, promoting the employment-oriented enterprises and not expanding government offices having similar nature of work in the three levels, among others.(RSS)What to Know About the Fresno State Grad Who Is Trump’s Pick for Labor SecretaryJudge rejects request to sideline a San Jose State volleyball player on grounds she’s transgender